1003048-72-3

Basic information

• Product Name: 4-broMo-7-fluoro-2,3-dihydroinden-1-one
• Synonyms: 4-broMo-7-fluoro-2,3-dihydroinden-1-one;4-BroMo-7-fluoro-2,3-dihydro-1H-inden-1-one;4-Bromo-2,3-dihydro-7-fluoro-1H-inden-1-one, 4-Bromo-2,3-dihydro-7-fluoro-1-oxo-1H-indene;4-Bromo-7-fluoroindan-1-one;4-Bromo-7-fluoro-1-indanone
• CAS NO: 1003048-72-3
• Molecular Formula: C₉H₆BrFO
• Molecular Weight: 229.0457432
• EINECS: -0
• Mol File: 1003048-72-3.mol

Chemical Properties

• Boiling Point: 310.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.691±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 4-broMo-7-fluoro-2,3-dihydroinden-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 4-broMo-7-fluoro-2,3-dihydroinden-1-one(1003048-72-3)
• EPA Substance Registry System: 4-broMo-7-fluoro-2,3-dihydroinden-1-one(1003048-72-3)

Safety Data

• Hazardous Substances Data: 1003048-72-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-bromo-7-fluoro-2,3-dihydroinden-1-one is used as a reactant or reagent for the preparation of indanyloxydihydrobenzofuranylacetic acids. These acids are suitable for the treatment of metabolic diseases, making this compound a valuable asset in the development of pharmaceuticals aimed at addressing such health conditions.

Upstream product

• 651735-59-0 7-fluoro-2,3-dihydro-1H-inden-1-one 

Downstream Products

• 1458657-24-3 2-((S)-6-((R)-4-(2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 1458653-87-6 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-(3-(methylsulfonyl)propoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-59-1 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-((1-methyl-1H-pyrazol-3-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-60-4 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-((1-methyl-2-oxo-1,2-dihydropyridin-4-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-61-5 methyl 2-((S)-6-((R)-7-fluoro-4-(4-((2-methoxypyridin-4-yl)methoxy)-2,6-dimethylphenyl)-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-62-6 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-(oxazol-2-ylmethoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-63-7 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-((1-methyl-1H-imidazol-2-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-64-8 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-((tetrahydro-2H-pyran-4-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-65-9 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-((1-methyl-1H-pyrazol-5-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-66-0 methyl 2-((S)-6-((R)-4-(2,6-dimethyl-4-((1-methyl-1H-pyrazol-4-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetate 
• 1458656-68-2 2-((S)-6-((R)-4-(2,6-dimethyl-4-((3-methyloxetan-3-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 1458656-69-3 2-((3S)-6-((1R)-4-(2,6-dimethyl-4-((tetrahydrofuran-3-yl)methoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 1458656-72-8 2-((3S)-6-((1R)-4-(2,6-dimethyl-4-(2-(methylsulfinyl)ethoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 
• 1458656-73-9 2-((S)-6-((R)-4-(2,6-dimethyl-4-(2-(methylsulfonyl)ethoxy)phenyl)-7-fluoro-2,3-dihydro-1H-inden-1-yloxy)-2,3-dihydrobenzofuran-3-yl)acetic acid 

Relevant articles and documents

SUBSTITUTED DIHYDROINDENE-4-CARBOXAMIDES AND ANALOGS THEREOF, AND METHODS USING SAME

The present invention includes novel substituted bicyclic compounds, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient. In certain embodiments, the compounds and compositions of the invention are capsid inhibitors. (Formula I)

TRPV1 Antagonists

Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, Rz, A, m, n, p, q, s, and positions a and b are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.

AMINOINDAN DERIVATIVE OR SALT THEREOF

Provided is a compound that is an NMDA receptor antagonist having a broader safety margin, and is useful as an agent for treating or preventing Alzheimer's disease, cerebrovascular dementia, Parkinson's disease, ischemic apoplexy, or pain. A novel compound or a salt thereof, which is characterized in that it has an amino group and R1(lower alkyl, cycloalkyl, -lower alkylene-aryl, aryl which may be substituted, and the like) on carbon atoms of indane, cyclopenta[b]thiophene, cyclopenta[b]furan, cyclopenta[b]pyridine, or cyclopenta[c]pyridine ring, or 2,3-dihydrdo-1-benzofuran, 2,3-dihydrdo-1-benzothiophene, indoline ring, or the like, and has R2 and R3 (the same or different, each lower alkyl or aryl) on carbon atoms beside them, and an NMDA receptor antagonist comprising the same as an active component.